2,400-Patient Trial Utilizes Globally-Respected SWEDEHEART Registry Database in Randomized Study of First Metallic Device Treating Coronary Artery Disease That Adapts to Vessel Physiology MILPITAS, Calif.–(BUSINESS WIRE)–Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, today announced commencement of the INFINITY-SWEDEHEART randomized controlled trial (RCT) of the DynamX™ Coronary Bioadaptor System, the […]
Tag: Elixir Medical
Elixir Medical Announces First Patient Treated in BIOADAPTOR Randomized Controlled Trial of DynamX Coronary Bioadaptor System
International Trial to Compare Bioadaptor, a Novel Coronary Artery Implant Designed to Adapt to Vessel Physiology, with Traditional Drug Eluting Stents MILPITAS, Calif.–(BUSINESS WIRE)–Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, today announced that the first patient has been treated in the BIOADAPTOR randomized controlled trial (RCT) of the DynamX™ […]
Elixir Medical Announces Outstanding 9 and 12-Month Clinical and Imaging Results for the Transformational DynamX™ Bioadaptor at EuroPCR
MILPITAS, Calif. & PARIS–(BUSINESS WIRE)–Elixir Medical Corporation, a developer of products that combine state-of-the-art medical devices with advanced pharmaceuticals, announced at EuroPCR excellent 9 and 12-month clinical and imaging data for the DynamX™ Novolimus-eluting Bioadaptor System, a next-generation coronary intervention system designed to treat blocked arteries via a novel vessel […]
Elixir Medical Corporation Unveils Transformational DynamX™ Stent Featuring Adaptive Segments that Uncage the Stented Artery
MILPITAS, Calif.–(BUSINESS WIRE)– Elixir Medical, a leader in the development of breakthrough adaptive remodeling technologies designed to mimic the normal arterial function after cardiovascular and peripheral vascular disease intervention, unveiled for the first time its novel stent technology, DynamXTM, a bioadaptive drug eluting stent (BA-DES) platform at the Transcatheter Cardiovascular Therapeutics […]
